Responses
Regular and Young Investigator Award Abstracts
Clinical Trial Completed
582 Analysis of the HR+/HER2- breast cancer tumor microenvironment following immune priming with pelareorep and atezolizumab using imaging mass cytometry – Results from the AWARE-1 trial
Compose a Response to This Article
Other responses
No responses have been published for this article.
